Association between aspirin use and cancer risk
| Cases (n=601,733) Exposed/unexposed | Controls (n=2,406,932) Exposed/unexposed | Unadjusted odds ratio (95% CI) | p Value | Adjusted odds ratio* (95% CI) | p Value | |
|---|---|---|---|---|---|---|
| Cancers | ||||||
| Overall | 88,153/513,580 | 353,001/2,053,931 | 1.00 (0.99 to 1.01) | 0.74 | 0.95 (0.94 to 0.96) | <0.001 |
| Colorectal | 14,850/71,747 | 58,175/288,213 | 1.03 (1.01 to 1.05) | 0.01 | 0.97 (0.94 to 0.99) | 0.004 |
| Digestive | 20,575/10,1359 | 82,717/405,019 | 0.99 (0.98 to 1.01) | 0.46 | 0.96 (0.94 to 0.98) | <0.001 |
| Gastric | 4,158/18,416 | 17,096/73,200 | 0.96 (0.93 to 1.00) | 0.07 | 0.96 (0.92 to 1.00) | 0.057 |
| Breast | 4,853/60,638 | 192,662/242,702 | 1.01 (0.98 to 1.04) | 0.60 | 0.99 (0.96 to 1.03) | 0.757 |
| Lung | 12,999/55,410 | 52,528/221,108 | 0.99 (0.97 to 1.01) | 0.23 | 0.95 (0.92 to 0.97) | <0.001 |
| Prostate | 7,946/24,473 | 30,473/99,203 | 1.06 (1.03 to 1.09) | 0.00 | 1.03 (0.99 to 1.06) | 0.104 |
p<0.001.
*Adjusted ORs were adjusted for the confounders such as comorbid conditions and other drugs in the analysis.